Donge Tang
Impact in
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Immunology top 10%
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
Papers in
- Nephrology 26
- Renal Diseases and Glomerulopathies 13
-
- MicroRNA in disease regulation 15
- Cancer-related molecular mechanisms research 14
- Co-authors
- Yong DaiLianghong YinXiaoping HongDongzhou LiuFengping ZhengMinglin OuWeier DaiWenbiao Chen
- Journals
- Frontiers in Immunology (14 papers)ACS Omega (5 papers)Journal of Translational Medicine (5 papers)Journal of Proteomics (4 papers)Aging (4 papers)
- Partner nations
- ChinaUnited StatesGermany
In The Last Decade
Donge Tang
143 papers receiving 1.8k citations
Peers
Comparison fields: 5 of 111
- Cancer Research 395
- Immunology 413
- Rheumatology 266
- Nephrology 108
- Molecular Biology 1.0k
Countries citing papers authored by Donge Tang
This map shows the geographic impact of Donge Tang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donge Tang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donge Tang more than expected).
Fields of papers citing papers by Donge Tang
This network shows the impact of papers produced by Donge Tang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donge Tang. The network helps show where Donge Tang may publish in the future.
Co-authors
The 25 scholars most cited alongside Donge Tang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2024 | 1 | |
| 3 | 2023 | 12 | |
| 4 | 2023 | 6 | |
| 5 | 2023 | 3 | |
| 6 | 2023 | 12 | |
| 7 | 2023 | 2 | |
| 8 | 2023 | 4 | |
| 9 | 2022 | 8 | |
| 10 | 2022 | 32 | |
| 11 | 2022 | 12 | |
| 12 | 2022 | 11 | |
| 13 | 2022 | 1 | |
| 14 | 2021 | 5 | |
| 15 | 2021 | 54 | |
| 16 | 2021 | 9 | |
| 17 | 2021 | 8 | |
| 18 | 2021 | 8 | |
| 19 | 2020 | 8 | |
| 20 | 2019 | 8 |
About Donge Tang
Donge Tang is a scholar working on Nephrology, Cancer Research, Transplantation, Molecular Biology and Rheumatology, having authored 149 papers that have together received 1.8k indexed citations. Recurring topics across this work include RNA modifications and cancer (19 papers), Epigenetics and DNA Methylation (16 papers), MicroRNA in disease regulation (15 papers), Systemic Lupus Erythematosus Research (14 papers), Cancer-related molecular mechanisms research (14 papers), Ferroptosis and cancer prognosis (13 papers), Renal Diseases and Glomerulopathies (13 papers) and Ubiquitin and proteasome pathways (11 papers). The work is most often cited by research in Cancer Research (395 citations), Immunology (413 citations), Rheumatology (266 citations), Nephrology (108 citations) and Molecular Biology (1.0k citations). Donge Tang has collaborated with scholars based in China, United States and Germany. Frequent co-authors include Yong Dai, Lianghong Yin, Xiaoping Hong, Dongzhou Liu, Fengping Zheng, Minglin Ou, Weier Dai, Wenbiao Chen, Wanxia Cai and Weiguo Sui. Their work appears in journals such as Frontiers in Immunology, ACS Omega, Journal of Translational Medicine, Journal of Proteomics and Aging.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.